Text Size

A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost/timolol fixed-dose combination therapy

Holló G, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Oddone F; VISIONARY Study Group


  • 2022
  • Current Medical Research and Opinion
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Post-Approval studies/RWE

  • Affiliations

    Tutkimusz Ltd., Solymár, Hungary; Eye Center, Prima Medica Health Centers, Budapest, Hungary; Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Portsmouth, UK; Department of Ophthalmology, Instituto Oftalmologico Gomez-Ulla, Santiago de Compostela, Galicia, Spain; Department of Ophthalmology, LLC Vzglyad, Leningradskaya, Chita, Russia; Medical Affairs, Santen SA, Geneva, Switzerland; Glaucoma Unit, IRCSS-Fondazione Bietti, Rome, Italy

Related Publications

An Exploratory Study of Machine Learning-Based Open-Angle Glaucoma Detection Using Specific Autoantibodies

Takada N., Ishikawa M., Ninomiya T., Izumi Y., Sato K., Kunikata H., Yokoyama Y., Tsuda S., Fukuda E., Yamaguchi K., Ono C., Kirihara T., Shintani C., Hanyuda A., Goshima N., Zorumski C.F., NakazawaT.


Relaxation of Precontracted Ciliary Artery and Ciliary Muscle In Vitro by Kinin Peptides: Relevance to Retinal Blood Flow and Intraocular Pressure Regulation

Sharif N.A., Kulkarni-Chitnis M., Okolie A., Chaudhry S.D., Njie-Mbye Y.F., Ohia S.E.


The Role of EP3 Agonism in Intraocular Pressure-Lowering by Sepetaprost, a Novel Dual Agonist of FP and EP3 Receptors, in Monkeys

Maki K., Kimura E., Yamamoto Y., Fuwa M., Toris C.B., Fan S., Shimazaki A., Kato M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022